As the Institute for Clinical and Economic Review's (ICER) influence on payer behaviour and health policy grows, how should pharma respond? The ICER's novel and inclusive work on the value of drugs, using its own value...

Where will CRISPR deliver real value? Investors and pharma are enthusiastic about CRISPR gene editing technology: not only can it be used to develop new therapeutics, it has become a powerful tool in drug discovery,...

What are the trends and developments that will drive pharma's digital marketing initiatives? What are the trends that are shaping digital pharma marketing? How will increased investment be used to drive the digital...

How are market access teams developing to meet evolving stakeholder demands? What are the trends that are defining market access skills? Which core competencies should teams be developing for the future? What market...

The key to commercial success for biosimilars? Find out what the experts say The biosimilars market is in a state of flux as key players in the US and Europe actively seek to improve perceptions, shape the market, and...

How do Real World Data (RWD) and Real World Evidence (RWE) professionals see their critical role developing? Which teams are using RWD/RWE, where is it providing most value and how might this change over the next 2...

Building the most effective strategy for fast track market access Getting to market faster clearly has benefits, but there are also potential downsides for drug companies too. You need to know the options and consider...

What do payers see as critical to unlocking the stalled US biosimilar sector? How do payers view the trends in the sluggish US biosimilar market and what initiatives do they want from pharma? Originator companies are...